Systematic multi-trait AAV capsid engineering for efficient gene delivery
- PMID: 39097583
- PMCID: PMC11297966
- DOI: 10.1038/s41467-024-50555-y
Systematic multi-trait AAV capsid engineering for efficient gene delivery
Abstract
Broadening gene therapy applications requires manufacturable vectors that efficiently transduce target cells in humans and preclinical models. Conventional selections of adeno-associated virus (AAV) capsid libraries are inefficient at searching the vast sequence space for the small fraction of vectors possessing multiple traits essential for clinical translation. Here, we present Fit4Function, a generalizable machine learning (ML) approach for systematically engineering multi-trait AAV capsids. By leveraging a capsid library that uniformly samples the manufacturable sequence space, reproducible screening data are generated to train accurate sequence-to-function models. Combining six models, we designed a multi-trait (liver-targeted, manufacturable) capsid library and validated 88% of library variants on all six predetermined criteria. Furthermore, the models, trained only on mouse in vivo and human in vitro Fit4Function data, accurately predicted AAV capsid variant biodistribution in macaque. Top candidates exhibited production yields comparable to AAV9, efficient murine liver transduction, up to 1000-fold greater human hepatocyte transduction, and increased enrichment relative to AAV9 in a screen for liver transduction in macaques. The Fit4Function strategy ultimately makes it possible to predict cross-species traits of peptide-modified AAV capsids and is a critical step toward assembling an ML atlas that predicts AAV capsid performance across dozens of traits.
© 2024. The Author(s).
Conflict of interest statement
BED is a scientific founder at Apertura Gene Therapy and a scientific advisory board member at Tevard Biosciences. BED, FEE, and KYC are named inventors on patent applications filed by the Broad Institute of MIT and Harvard related to the design and use of Fit4Function libraries (WO2021222636) and AAV sequences developed as part of this study. The remaining authors declare that they have no competing interests.
Figures
References
MeSH terms
Substances
Grants and funding
- R01 DK078616/DK/NIDDK NIH HHS/United States
- UG3MH120096/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- P51 OD011107/OD/NIH HHS/United States
- U01 MH121499/MH/NIMH NIH HHS/United States
- U01 DK078616/DK/NIDDK NIH HHS/United States
- UG3 MH120096/MH/NIMH NIH HHS/United States
- P51-OD011107/U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD)
- UM1 DK078616/DK/NIDDK NIH HHS/United States
- UG3NS111689/U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD)
- UG3 NS111689/NS/NINDS NIH HHS/United States
- R01 MH109903/MH/NIMH NIH HHS/United States
- U42 OD027094/OD/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
